Aosaikang Pharmaceutical announced on December 22 that its subsidiary, Jiangsu Aosaikang Pharmaceutical Co., Ltd., has received the Drug Registration Certificate for Delafloxacin Meglumine for Injection approved and issued by the National Medical Products Administration (NMPA).
Registered as a Class 3 chemical drug in injection dosage form with a specification of 0.3g (calculated as C18H12ClF3N4O4cap C sub 18 cap H sub 12 cap C l cap F sub 3 cap N sub 4 cap O sub 4𝐶18𝐻12𝐶𝑙𝐹3𝑁4𝑂4), the drug is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
As a novel broad-spectrum antibiotic, Delafloxacin demonstrates extensive and potent antibacterial activity against Gram-positive (G+cap G raised to the positive power𝐺+) bacteria, Gram-negative (G−cap G raised to the negative power𝐺−) bacteria, and anaerobic bacteria. Compared to other fluoroquinolone antibiotics, Delafloxacin possesses unique anionic properties, which enhance its antibacterial activity in acidic environments. Its drug accumulation in acidic environments can reach up to 10 times that of other fluoroquinolones, providing superior antibacterial efficacy against Methicillin-resistant Staphylococcus aureus (MRSA) and other pathogens.

https://finance.eastmoney.com/a/202512223598477566.html